EMA to review Gilead application for hepatitis C drugs

23-01-2017

EMA to review Gilead application for hepatitis C drugs

Oleksii Fedorenko / shutterstock.com

Gilead’s marketing authorisation application for sofosbuvir 400mg, velpatasvir 100mg and voxilaprevir 100mg—treatments for chronic hepatitis C virus (HCV)—is under assessment by the European Medicines Agency (EMA).


EMA, Gilead, hepatitis C, FDA, marketing authorisation

LSIPR